CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84.77
가격 · 8월 19, 2026
기준 재무 정보 8월 3, 2026
52주 범위
$29–$85
100% of range
애널리스트 평점
HOLD
21 analysts
목표 주가
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
순이익률
-6046.2%
Crinetics Pharmaceuticals, Inc. - Common Stock 정보 위키백과 회사 개요
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
더 보기
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
CRNX 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$84.77
시가총액
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
매출 (TTM)
$8M
배당 수익률
—
ROE
-43.0%
부채/자본
—
52주 범위
$29 – $85
CRNX 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
잉여현금흐름
$-384M
2018-12-31
→
2025-12-31
마진
-6046.2%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
CRNX
동종업계 중앙값
P/E (TTM)
-17.1
47.9
P/S (TTM)
1052.7
16.2
P/B
8.2
9.3
Price / FCF (주가 / FCF)
-21.1
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
CRNX
동종업계 중앙값
Operating Margin (영업이익률)
-6714.8%
—
Net Profit Margin (순이익률)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
CRNX
동종업계 중앙값
Current Ratio (유동비율)
12.3
2.7
Quick Ratio (당좌 비율)
12.1
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
CRNX
동종업계 중앙값
Revenue YoY (매출 YoY)
640.7%
—
Revenue CAGR 3Y (매출 CAGR 3년)
17.6%
—
Revenue CAGR 5Y (매출 CAGR 5년)
155.3%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
CRNX
동종업계 중앙값
CRNX 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
보유
21 명의 애널리스트
- 적극 매수 3 14.3%
- 매수 4 19.0%
- 보유 14 66.7%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
10 명의 애널리스트 · 2026-08-13
중앙값
$85.00
평균
$85.50
← 모든 목표가 하회
$84.77
저가
$85.00
고가
$90.00
중앙값 목표
$85.00
+0.3%
평균 목표
$85.50
+0.9%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
-0.01%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-1.14 | $-1.23 | 0.09% |
| 2026년 3월 31일 | $-1.23 | $-1.26 | 0.03% |
| 2025년 12월 31일 | $-1.29 | $-1.39 | 0.10% |
| 2025년 9월 30일 | $-1.38 | $-1.28 | -0.10% |
| 2025년 6월 30일 | $-1.23 | $-1.12 | -0.11% |
| 2025년 3월 31일 | $-1.04 | $-0.96 | -0.08% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
대차대조표 24
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
현금 흐름 13
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
유동성 및 지급능력 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
손익계산서 15
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
대차대조표 23
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
현금 흐름 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
수익성 6
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
유동성 및 지급능력 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
효율성 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $8M | $1M | $4M | $5M | $1M |
| 영업이익률 % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| 순이익 | $-465M | $-298M | $-215M | $-164M | $-108M |
| 희석 EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| 당좌 비율 | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-384M | $-230M | $-171M | $-117M | $-89M |
최신 뉴스 이 회사 관련 최근 헤드라인
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 287개의 제출자 · $3.2B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 63 (+17 이전 분기 대비) | 30 (-14 이전 분기 대비) | 95 (-17 이전 분기 대비) | 63 (+3 이전 분기 대비) | +21.6M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| FMR LLC | $486,250,673 | 12,994,406 | 15.13% | 주식 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336,372,047 | 8,989,098 | 10.46% | 주식 |
| Driehaus Capital Management LLC | $241,866,078 | 6,463,551 | 7.52% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $237,002,526 | 6,333,579 | 7.37% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180,836,416 | 4,832,614 | 5.63% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $177,567,704 | 4,745,262 | 5.52% | 주식 |
| STATE STREET CORP | $100,635,477 | 2,689,350 | 3.13% | 주식 |
| Bellevue Group AG | $98,040,400 | 2,620,000 | 3.05% | 주식 |
| BAKER BROS. ADVISORS LP | $87,991,820 | 2,351,465 | 2.74% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $87,542,675 | 2,338,905 | 2.72% | 주식 |
| Polar Capital Holdings Plc | $85,108,460 | 2,274,411 | 2.65% | 주식 |
| Pictet Asset Management Holding SA | $77,572,984 | 2,075,375 | 2.41% | 주식 |
| Siren, L.L.C. | $53,165,887 | 1,420,788 | 1.65% | 주식 |
| First Light Asset Management, LLC | $50,923,606 | 1,360,866 | 1.58% | 주식 |
| NOVO HOLDINGS A/S | $49,394,400 | 1,320,000 | 1.54% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $47,245,129 | 1,262,562 | 1.47% | 주식 |
| ADAR1 Capital Management, LLC | $45,730,234 | 1,222,080 | 1.42% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $44,555,208 | 1,190,679 | 1.39% | 주식 |
| MONTANOVA CAPITAL, LLC | $44,390,560 | 1,186,279 | 1.38% | 주식 |
| ORBIMED ADVISORS LLC | $37,382,580 | 999,000 | 1.16% | 주식 |
| Hood River Capital Management LLC | $36,259,830 | 968,996 | 1.13% | 주식 |
| GOLDMAN SACHS GROUP INC | $34,657,132 | 926,166 | 1.08% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32,841,401 | 877,643 | 1.02% | 주식 |
| Aberdeen Group plc | $30,699,181 | 820,395 | 0.95% | 주식 |
| Candriam S.C.A. | $30,618,690 | 819,032 | 0.95% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $28,230,995 | 754,436 | 0.88% | 주식 |
| Fisher Asset Management, LLC | $27,748,912 | 741,553 | 0.86% | 주식 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17,709,036 | 479,400 | 0.55% | 주식 |
| AMERIPRISE FINANCIAL INC | $17,451,149 | 466,356 | 0.54% | 주식 |
| Impax Asset Management Group plc | $16,277,700 | 435,000 | 0.51% | 주식 |
| Prosight Management, LP | $14,020,002 | 374,666 | 0.44% | 주식 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13,991,714 | 373,910 | 0.44% | 주식 |
| KENNEDY CAPITAL MANAGEMENT LLC | $13,685,018 | 365,714 | 0.43% | 주식 |
| BRAUN STACEY ASSOCIATES INC | $13,027,511 | 348,143 | 0.41% | 주식 |
| Fiera Capital Corp | $12,395,263 | 331,247 | 0.39% | 주식 |
| BANK OF AMERICA CORP /DE/ | $11,271,877 | 301,226 | 0.35% | 주식 |
| Defilade Capital Management, L.P. | $8,959,845 | 239,440 | 0.28% | 주식 |
| SEB Asset Management AB | $8,003,786 | 213,891 | 0.25% | 주식 |
| Foresite Capital Management VI LLC | $7,933,414 | 212,010 | 0.25% | 주식 |
| RICE HALL JAMES & ASSOCIATES, LLC | $7,346,220 | 196,318 | 0.23% | 주식 |
| TD Asset Management Inc | $7,152,534 | 191,142 | 0.22% | 주식 |
| Swiss National Bank | $6,877,796 | 183,800 | 0.21% | 주식 |
| SEGALL BRYANT & HAMILL, LLC | $6,855,307 | 183,199 | 0.21% | 주식 |
| BlackRock, Inc. | $6,781,290 | 181,221 | 0.21% | 주식 |
| JENNISON ASSOCIATES LLC | $6,056,839 | 161,861 | 0.19% | 주식 |
| New Leaf Venture Partners, L.L.C. | $5,872,650 | 141,000 | 0.18% | 주식 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5,865,136 | 156,738 | 0.18% | 주식 |
| Foresite Capital Management IV, LLC | $5,613,000 | 150,000 | 0.17% | 주식 |
| Bank of New York Mellon Corp | $5,581,754 | 149,165 | 0.17% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $5,508,898 | 147,218 | 0.17% | 주식 |
| ENVESTNET ASSET MANAGEMENT INC | $5,471,384 | 146,216 | 0.17% | 주식 |
| Moody Aldrich Partners LLC | $5,466,201 | 146,077 | 0.17% | 주식 |
| Ishara Investments LP | $5,369,770 | 143,500 | 0.17% | 주식 |
| CITADEL ADVISORS LLC | $5,176,271 | 138,329 | 0.16% | 주식 |
| RHUMBLINE ADVISERS | $4,861,141 | 129,908 | 0.15% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $4,782,618 | 131,680 | 0.15% | 주식 |
| GordonMD Global Investments LP | $4,751,779 | 126,985 | 0.15% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4,712,974 | 125,948 | 0.15% | 주식 |
| JANUS HENDERSON GROUP PLC | $4,700,428 | 129,392 | 0.15% | 주식 |
| Cormorant Asset Management, LP | $4,677,500 | 125,000 | 0.15% | 주식 |
| SECTOR GAMMA AS | $4,289,380 | 114,628 | 0.13% | 주식 |
| XTX Topco Ltd | $4,164,547 | 111,292 | 0.13% | 주식 |
| ALPS ADVISORS INC | $3,981,825 | 106,409 | 0.12% | 주식 |
| FEDERATED HERMES, INC. | $3,957,390 | 105,756 | 0.12% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3,834,048 | 105,563 | 0.12% | 주식 |
| Nuveen Asset Management, LLC | $3,760,151 | 73,541 | 0.12% | 주식 |
| Burkehill Global Management, LP | $3,742,000 | 100,000 | 0.12% | 주식 |
| Nuveen, LLC | $3,619,262 | 96,720 | 0.11% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $3,484,251 | 93,112 | 0.11% | 주식 |
| MORGAN STANLEY | $3,320,829 | 88,744 | 0.10% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $3,266,729 | 87,299 | 0.10% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $3,254,754 | 86,979 | 0.10% | 주식 |
| AWM Investment Company, Inc. | $3,180,700 | 85,000 | 0.10% | 주식 |
| Odyssean, LLC | $3,160,344 | 84,456 | 0.10% | 주식 |
| Affinity Asset Advisors, LLC | $2,806,500 | 75,000 | 0.09% | 주식 |
| ALGERT GLOBAL LLC | $2,714,147 | 72,532 | 0.08% | 주식 |
| ExodusPoint Capital Management, LP | $2,652,404 | 70,882 | 0.08% | 주식 |
| Ensign Peak Advisors, Inc | $2,507,290 | 67,004 | 0.08% | 주식 |
| BARCLAYS PLC | $2,466,127 | 65,904 | 0.08% | 주식 |
| FIRST TRUST ADVISORS LP | $2,370,631 | 63,352 | 0.07% | 주식 |
| Man Group plc | $2,284,229 | 61,043 | 0.07% | 주식 |
| MetLife Investment Management, LLC | $2,258,709 | 60,361 | 0.07% | 주식 |
| CITIGROUP INC | $2,255,229 | 60,268 | 0.07% | 주식 |
| Longaeva Partners L.P. | $2,184,879 | 58,388 | 0.07% | 주식 |
| Swedbank AB | $2,155,392 | 57,600 | 0.07% | 주식 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,068,016 | 55,265 | 0.06% | 주식 |
| Jump Financial, LLC | $1,923,388 | 51,400 | 0.06% | 주식 |
| Lighthouse Investment Partners, LLC | $1,871,000 | 50,000 | 0.06% | 주식 |
| Vestmark Advisory Solutions, Inc. | $1,823,252 | 48,724 | 0.06% | 주식 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1,787,254 | 47,762 | 0.06% | 주식 |
| VANGUARD GROUP INC | $1,774,626 | 38,123 | 0.06% | 주식 |
| Point72 Asset Management, L.P. | $1,735,577 | 46,381 | 0.05% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $1,696,398 | 45,334 | 0.05% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $1,606,254 | 42,925 | 0.05% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,549,188 | 41,400 | 0.05% | 콜 옵션 |
| Invesco Ltd. | $1,545,446 | 41,300 | 0.05% | 주식 |
| Vanguard Global Advisers, LLC | $1,485,986 | 39,711 | 0.05% | 주식 |
| HighMark Wealth Management LLC | $1,444,224 | 38,595 | 0.04% | 주식 |
| OAK RIDGE INVESTMENTS LLC | $1,405,046 | 37,548 | 0.04% | 주식 |
| Orion Porfolio Solutions, LLC | $1,404,234 | 37,526 | 0.04% | 주식 |
회사 내부자 20 명의 내부자 · 9 임원 · 10 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 2025년 3월 10일 A | 52,000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 2024년 9월 26일 M | 111,092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 2025년 3월 19일 S | 87,491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 2025년 6월 12일 M | 99,713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 2025년 3월 19일 S | 72,233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 2025년 1월 10일 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 2024년 7월 5일 M | 29,259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 2023년 10월 17일 M | 43,210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 2022년 2월 28일 A | 176,995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | 이사 | 2026년 7월 2일 S | 19,225 | 0 | 1 | $-120,000 |
| Caren Deardorf | 이사 | 2026년 6월 18일 A | 22,225 | 0 | 0 | $0 |
| Weston Nichols | 이사 | 2026년 6월 18일 A | 22,225 | 0 | 0 | $0 |
| Stephanie Okey | 이사 | 2026년 6월 18일 A | 12,325 | 0 | 2 | $-246,143 |
| Matthew K Fust | 이사 | 2026년 6월 18일 A | 28,761 | 0 | 0 | $0 |
| Camille L Bedrosian | 이사 | 2026년 6월 18일 A | 22,225 | 0 | 0 | $0 |
| Wendell Wierenga | 이사 | 2026년 6월 18일 A | 122,071 | 0 | 0 | $0 |
| Wendall Wierenga | 이사 | 2025년 6월 11일 A | 116,146 | 0 | 0 | $0 |
| Stephen W Kaldor | 이사 | 2020년 6월 19일 A | — | 0 | 0 | $0 |
| Jack Nielsen | 이사 | 2019년 6월 21일 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 2026년 8월 7일 M | 424,706 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 1 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 제출 서류 | 2024년 3월 1일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 55 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2.37% | 107,892 NS | 2026년 5월 31일 | N-PORT |
| IHE · iShares Trust | 1.95% | 376,636 SH | 2026년 8월 8일 | 일간 |
| FMED · Fidelity Covington Trust | 1.65% | 19,000 NS | 2026년 5월 31일 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1.40% | 4,666 NS | 2026년 4월 30일 | N-PORT |
| BBP · ETFis Series Trust I | 1.23% | 18,743 NS | 2026년 4월 30일 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0.75% | 11,043 NS | 2026년 5월 31일 | N-PORT |
| IBB · iShares Trust | 0.63% | 718,323 SH | 2026년 8월 8일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.60% | 5,737 SH | 2026년 8월 8일 | 일간 |
| IWO · iShares Trust | 0.54% | 940,202 SH | 2026년 8월 8일 | 일간 |
| NUSC · Nushares ETF Trust | 0.28% | 93,045 NS | 2026년 4월 30일 | N-PORT |
| ISCG · iShares Trust | 0.27% | 32,694 SH | 2026년 8월 8일 | 일간 |
| IWM · iShares Trust | 0.27% | 2,625,192 SH | 2026년 8월 8일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.23% | 110,770 SH | 2026년 8월 8일 | 일간 |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.20% | 38,553 NS | 2026년 4월 30일 | N-PORT |
| BIB · ProShares Trust | 0.19% | 3,872 NS | 2026년 5월 31일 | N-PORT |
| ESML · iShares Trust | 0.16% | 55,438 SH | 2026년 8월 8일 | 일간 |
| BKSE · BNY Mellon ETF Trust | 0.15% | 3,142 NS | 2026년 4월 30일 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.15% | 51,135 SH | 2026년 8월 8일 | 일간 |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.14% | 18,879 NS | 2026년 4월 30일 | N-PORT |
| ISCB · iShares Trust | 0.13% | 4,625 SH | 2026년 8월 8일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.12% | 596,648 SH | 2026년 8월 8일 | 일간 |
| RSSL · Global X Funds | 0.12% | 42,391 NS | 2026년 4월 30일 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.11% | 1,399,667 SH | 2026년 8월 8일 | 일간 |
| FFSM · FIDELITY COVINGTON TRUST | 0.10% | 31,759 NS | 2026년 4월 30일 | N-PORT |
| ITWO · ProShares Trust | 0.09% | 4,601 NS | 2026년 5월 31일 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.09% | 2,909 SH | 2026년 8월 8일 | 일간 |
| SCHA · SCHWAB STRATEGIC TRUST | 0.08% | 492,431 NS | 2026년 5월 31일 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.07% | 24,991 NS | 2026년 4월 30일 | N-PORT |
| WSML · iShares Trust | 0.07% | 5,742 SH | 2026년 8월 8일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.06% | 41,183 NS | 2026년 4월 30일 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.05% | 196,549 NS | 2026년 4월 30일 | N-PORT |
| UWM · ProShares Trust | 0.05% | 3,599 NS | 2026년 5월 31일 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.05% | 2,419,186 SH | 2026년 8월 8일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.05% | 275,155 SH | 2026년 8월 8일 | 일간 |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.04% | 5,196 NS | 2026년 4월 30일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.04% | 1,210,574 SH | 2026년 8월 8일 | 일간 |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.04% | 112 NS | 2026년 5월 31일 | N-PORT |
| URTY · ProShares Trust | 0.04% | 3,643 NS | 2026년 5월 31일 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.02% | 5,689 NS | 2026년 5월 31일 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.02% | 3,773 NS | 2026년 5월 31일 | N-PORT |
| HDG · ProShares Trust | 0.02% | 91 NS | 2026년 5월 31일 | N-PORT |
| ITOT · iShares Trust | 0.01% | 146,419 SH | 2026년 8월 8일 | 일간 |
| IWV · iShares Trust | 0.01% | 27,043 SH | 2026년 8월 8일 | 일간 |
| DFAC · Dimensional ETF Trust | 0.01% | 125,853 NS | 2026년 4월 30일 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.01% | 3,342,704 SH | 2026년 8월 8일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 8,345 SH | 2026년 8월 8일 | 일간 |
| ESGV · VANGUARD WORLD FUND | 0.01% | 22,843 SH | 2026년 8월 8일 | 일간 |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 28,694 NS | 2026년 5월 31일 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 5,863 NS | 2026년 4월 30일 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 3,388 NS | 2026년 4월 30일 | N-PORT |